Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of amoxicillin, clarithromycin, and esomeprazole is a triple therapy medication used primarily for the treatment of Helicobacter pylori (H. pylori) infection and associated peptic ulcers. This combination therapy is designed to eradicate the H. pylori bacteria while reducing stomach acid production to promote healing of ulcers. Amoxicillin is a penicillin-type antibiotic, clarithromycin is a macrolide antibiotic, and esomeprazole is a proton pump inhibitor (PPI). The antibiotics work together to kill the H. pylori bacteria, while esomeprazole reduces stomach acid to create an environment that allows the ulcers to heal and enhances the effectiveness of the antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clarithromycin + esomeprazole.